Clinical Trials Browser

OTHER × Breast Neoplasms × Ado-Trastuzumab Emtansine × Clear all

NCT03587740 2026-05-18

ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer

Phase 2 Active not recruiting

111 enrolled 20 charts

Breast Neoplasms

NCT06663787 2026-05-13

HER2 CR

Active not recruiting

Breast Neoplasms, Neoplasm Metastasis, Neoplasm, Residual

NCT01042379 2026-05-06

I-SPY

Phase 2 Recruiting

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT04733118 2026-04-29

PHERGAIN-2

Phase 2 Active not recruiting

Breast Neoplasms

NCT04893109 2026-04-24

ATEMPT 2.0: Adjuvant T-DM1 vs TH

Phase 2 Recruiting

Breast Neoplasms

NCT02326974 2026-04-17

T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA

Phase 2 Active not recruiting

164 enrolled 19 charts

Breast Neoplasms

NCT02390427 2026-04-09

Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer

Phase 1 Completed

Breast Neoplasms

NCT07421141 2026-02-27

Opti-HER2

Phase 2 Active not recruiting

Breast Neoplasms

NCT01853748 2026-02-19

T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)

Phase 2 Completed

512 enrolled 28 charts

Breast Neoplasms

NCT06348134 2026-02-17

Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery

Phase 2 Recruiting

Breast Neoplasms

NCT02226276 2026-02-13

Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer

Phase NA Active not recruiting

10 enrolled 8 charts

Breast Neoplasms

NCT01494662 2026-01-23

HKI-272 for HER2-Positive Breast Cancer and Brain Metastases

Phase 2 Completed

140 enrolled 32 charts

Breast Neoplasms

NCT01975142 2025-11-24

Validity of HER2-amplified Circulating Tumor Cells to Select Metastatic Breast Cancer Considered HER2-negative for Trastuzumab-emtansine (T-DM1) Treatment.

Phase 2 Completed

Breast Neoplasms

NCT06439693 2025-06-26

The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT05288777 2025-04-18

Breast53

Phase 2/3 Recruiting

Breast Neoplasms

NCT04680442 2025-04-06

SCHOLAR-2

Phase 2 Recruiting

Breast Neoplasms, Heart Failure

NCT01565200 2025-03-31

ZEPHIR

Phase 2 Completed

Breast Neoplasms

NCT03032107 2025-01-27

A Study Of Pembrolizumab In Combination With Trastuzumab-DM1

Phase 1 Completed

20 enrolled 14 charts

Breast Neoplasms

NCT04675827 2024-12-04

Decrescendo

Phase 2 Terminated

Breast Neoplasms

NCT03530696 2024-08-13

T-DM1

Phase 2 Completed

55 enrolled 19 charts

Breast Neoplasms

NCT02448420 2024-04-18

PATRICIA II

Phase 2 Completed

Breast Neoplasms

NCT06299852 2024-03-08

Stereotactic Radiation Therapy for HE2-positive Oligometastatic Breast Cancer

Phase NA Unknown

Breast Neoplasms

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

Phase EARLY_PHASE1 Withdrawn

BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

NCT04197687 2023-12-18

TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery

Phase 2 Unknown

Breast Neoplasms

NCT04591431 2023-10-03

ROME

Phase 2 Unknown

BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms

NCT05754502 2023-03-03

Observational Study of Effectiveness and Safety of Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Residual Invasive Disease Following Neoadjuvant Chemotherapy and Anti-HER2 Target Therapy

Breast Neoplasms

NCT03364348 2022-10-19

4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer

Phase 1 Completed

18 enrolled 17 charts

Breast Neoplasms

NCT02657343 2022-08-01

An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.

Phase 1/2 Completed

25 enrolled 16 charts

Breast Neoplasms

NCT04351230 2022-05-26

T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer

Phase 2 Withdrawn

Breast Neoplasms

NCT04769050 2022-04-20

Dynamic Observational Study With PET of 68Ga-HER2-affibody in Anti-HER2 Treatment

Breast Neoplasms

NCT02562378 2022-02-23

THELMA

Phase 1 Completed

15 enrolled 39 charts

Breast Neoplasms

NCT01976169 2022-02-08

Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1)

Phase 1 Completed

Breast Neoplasms

NCT03894007 2021-09-23

PREDIXIIHER2

Phase 2 Terminated

Breast Neoplasms

NCT02073487 2021-09-22

TEAL

Phase 2 Completed

32 enrolled 7 charts

Breast Neoplasms

NCT01835236 2021-03-30

Trastuzumab & Pertuzumab Followed by T-DM1 in MBC

Phase 2 Completed

Breast Neoplasms, Neoplasm Metastasis

NCT02568839 2020-08-13

PREDIX HER2

Phase 2/3 Active not recruiting

Breast Neoplasms

NCT02038010 2020-06-29

BYL719 + T-DM1 in HER2(+) Metastatic Breast Cancer Pts Who Progress on Prior Trastuzumab & Taxane Tx

Phase 1 Completed

17 enrolled 17 charts

Breast Neoplasms

NCT02318901 2019-10-21

PembroMab

Phase 1/2 Terminated

16 enrolled 6 charts

BreastGastrointestinal

Breast Neoplasms, Esophageal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT02658084 2019-04-17

Vinorelbine With Trastuzumab Emtansine in Pre-Treated HER2-Positive Metastatic Breast Cancer

Phase 1/2 Terminated

2 enrolled 7 charts

Breast Neoplasms

NCT02073916 2019-04-16

STELA

Phase 1 Completed

Breast Neoplasms

NCT01816035 2017-05-23

Trastuzumab Emtansine in Treating Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed by Surgery

Phase 1 Completed

Breast Neoplasms

NCT02725541 2016-09-14

NATURE

Phase 2 Withdrawn

Breast Neoplasms